Immunotherapy represents one of the most important innovations in modern clinical oncology, and numerous solid tumors are currently treated with immune checkpoint inhibitors.

Durvalumab is an anti-PDL-1 agent which was introduced in clinical practice in 2017, while tremelimumab is an anti-CTLA-4 drug under investigation in several settings.

The combination of durvalumab plus tremelimumab has been recently investigated in thoracic, gastrointestinal, genitourinary, and other tumors.

We performed a systematic review of the literature and identified 19 articles reporting results on the combination of durvalumab plus tremelimumab.

Globally, the combination of these two drugs showed only sporadic benefits in comparison with the use of durvalumab alone or other treatments compared in the trials reviewed.